Skip Navigation


Annals of Oncology Advance Access originally published online on November 2, 2006
Annals of Oncology 2007 18(3):447-452; doi:10.1093/annonc/mdl407
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
18/3/447    most recent
mdl407v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Dziadziuszko, R
Right arrow Articles by Hirsch, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dziadziuszko, R
Right arrow Articles by Hirsch, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

lung cancer

Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small-cell lung cancer patients treated with chemotherapy

R Dziadziuszko1,2, B Holm3, BG Skov4, K Osterlind5, MV Sellers6, WA Franklin1, PA Bunn, Jr1, M Varella-Garcia1 and FR Hirsch1,*

1 University of Colorado Health Sciences Center, Aurora, CO, USA
2 Medical University of Gdansk, Gdansk, Poland
3 Herlev University Hospital, Herlev
4 Gentofte University Hospital, Copenhagen
5 Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
6 AstraZeneca, Macclesfield, UK

* Correspondence to: Dr F. R. Hirsch, Department of Medicine and Pathology, University of Colorado Cancer Center, PO Box 6511, Mail Stop 8117, Aurora, CO 80045, USA. Tel: +1 303 724 3858; Fax: +1 303 724 3889; E-mail: fred.hirsch{at}uchsc.edu

Background: Survival benefit of non-small-cell lung cancer (NSCLC) patients treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors is predicted by high EGFR gene copy number and by strong EGFR protein expression. Clinical relevance of these features in patients treated with chemotherapy has not been reported.

Patients and methods: This study included 82 NSCLC patients treated with chemotherapy. There were 45% of females, 6% of never smokers and 45% of patients diagnosed with adenocarcinoma. EGFR gene copy number was evaluated by fluorescence in situ hybridization and EGFR protein level by immunohistochemistry.

Results: High EGFR gene copy number and protein level were found in 33% and 71% of patients, respectively. Both markers were significantly associated (P = 0.01). For objective response and disease control, there was no difference between patients defined as negative or positive for both EGFR gene copy number (P = 0.39 and P = 1.00, respectively) and for EGFR protein (P = 1.00 and P = 0.80, respectively). There were no differences in progression-free and overall survival according to EGFR gene copy number (P = 0.76 and P = 0.82, respectively) and protein level (P = 0.67 and P = 0.62, respectively).

Conclusion: In chemotherapy-treated NSCLC patients, EGFR gene copy number was positively associated with protein level but none of the features were predictive for either treatment response or survival.

Key words: epidermal growth factor receptor, fluorescence in situ hybridization, gene copy number, immunohistochemistry, lung cancer, protein

Received for publication July 5, 2006. Revision received September 21, 2006. Accepted for publication September 25, 2006.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
J.-Y. Douillard, F. A. Shepherd, V. Hirsh, T. Mok, M. A. Socinski, R. Gervais, M.-L. Liao, H. Bischoff, M. Reck, M. V. Sellers, et al.
Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non-Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial
J. Clin. Oncol., February 10, 2010; 28(5): 744 - 752.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. R. Hirsch, R. S. Herbst, C. Olsen, K. Chansky, J. Crowley, K. Kelly, W. A. Franklin, P. A. Bunn Jr, M. Varella-Garcia, and D. R. Gandara
In Reply
J. Clin. Oncol., January 20, 2009; 27(3): 465 - 467.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. R. Hirsch, M. Varella-Garcia, R. Dziadziuszko, Y. Xiao, S. Gajapathy, M. Skokan, M. Lin, V. O'Neill, and P. A. Bunn Jr.
Fluorescence In situ Hybridization Subgroup Analysis of TRIBUTE, a Phase III Trial of Erlotinib Plus Carboplatin and Paclitaxel in Non-Small Cell Lung Cancer
Clin. Cancer Res., October 1, 2008; 14(19): 6317 - 6323.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
A. L. Van Dyke, M. L. Cote, G. M. Prysak, G. B. Claeys, A. S. Wenzlaff, V. C. Murphy, F. Lonardo, and A. G. Schwartz
COX-2/EGFR expression and survival among women with adenocarcinoma of the lung
Carcinogenesis, September 1, 2008; 29(9): 1781 - 1787.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. J. Weiss, L. T. Bemis, E. Nakajima, M. Sugita, D. K. Birks, W. A. Robinson, M. Varella-Garcia, P. A. Bunn Jr, J. Haney, B. A. Helfrich, et al.
EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines
Ann. Onc., June 1, 2008; 19(6): 1053 - 1059.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. L. Mueller, L. A. Hunter, S. P. Ethier, and J. L. Boerner
Met and c-Src Cooperate to Compensate for Loss of Epidermal Growth Factor Receptor Kinase Activity in Breast Cancer Cells
Cancer Res., May 1, 2008; 68(9): 3314 - 3322.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. Gridelli, M. A. Bareschino, C. Schettino, A. Rossi, P. Maione, and F. Ciardiello
Erlotinib in Non-Small Cell Lung Cancer Treatment: Current Status and Future Development
Oncologist, July 1, 2007; 12(7): 840 - 849.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
N van Zandwijk and M. van de Vijver
clairvoyance or reliable prediction of the future?
Ann. Onc., March 1, 2007; 18(3): 407 - 408.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.